Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113699432> ?p ?o ?g. }
- W2113699432 endingPage "283" @default.
- W2113699432 startingPage "275" @default.
- W2113699432 abstract "Background Preliminary studies in our laboratories indicate that a recently discovered synthetic drug, TBC-1269, acts as a multiple selectin blocker and provides protection against tissue damage in rats that are subjected to severe liver ischemia/reperfusion. Here, we report that this effect is dose and time dependent, with its effects acting through the modulation of tumor necrosis factor (TNF)-α and interleukin (IL)-10. Material and methods Mice subjected to 90 min of partial (70–80%) hepatic ischemia and 3 h of reperfusion were divided into eight groups (n = 6/group): sham, ischemic control (IC), three groups of TBC-1269-treated animals at different concentrations (10, 20, 40, mg/kg) and another three groups of TBC-1269 given at 40 mg/kg at different times of administration: 15 min prereperfusion but after ischemia (no pretreatment), at the time of reperfusion, and at 15 min after reperfusion. The parameters measured at 3 h of reperfusion included liver function tests (alanine aminotransferase and aspartate aminotransferase), histopathology analysis and measurements using enzyme-linked immunosorbent assay in serum of TNF-α and IL-10. Statistical analysis included analysis of variance with P values of <0.05 for significance. Results were expressed as mean ± SD. Results The liver function tests showed statistically significant differences between the ischemic control group and both the sham group and the group treated with 40 mg/kg at the time of reperfusion ([email protected]). These results correlated well with the histopathological analysis in that we found no difference in vacuolization, congestion, and necrosis between the [email protected] group and the sham group. The TNF-α and the IL-10 also reflected the protection observed in histopathology, with a decrease in TNF- α from the high levels observed in the IC (32 ± 2.32 pg/mL) to a lower level of 8.5 ± 4.04 mg observed in the [email protected] group, and an increment in the levels of the protective IL-10 from 2.8 ± 2.9 pg/mL in the IC group versus 37.9 ± 11.6 pg/mL in the [email protected] treated group (P < 0.05). Lower doses and different times of administration of TBC-1269 did not show a protective effect. The IC group showed no difference in damage by histopathology or liver enzymes compared to the rest of the groups, except the [email protected] group. Conclusion In this work, we demonstrated that the small molecule multiple selectin inhibitor (TBC-1269) offered significant protection for the ischemic liver when given at 40 mg/kg at the time of perfusion. Lower doses and different times of administration did not show the optimal drug effect. The protection observed in the liver function tests (alanine aminotransferase and aspartate aminotransferase) and histopathology in this group was also reflected in the significant decrease in serum TNF-α and equally significant increase in serum protective IL-10. Preliminary studies in our laboratories indicate that a recently discovered synthetic drug, TBC-1269, acts as a multiple selectin blocker and provides protection against tissue damage in rats that are subjected to severe liver ischemia/reperfusion. Here, we report that this effect is dose and time dependent, with its effects acting through the modulation of tumor necrosis factor (TNF)-α and interleukin (IL)-10. Mice subjected to 90 min of partial (70–80%) hepatic ischemia and 3 h of reperfusion were divided into eight groups (n = 6/group): sham, ischemic control (IC), three groups of TBC-1269-treated animals at different concentrations (10, 20, 40, mg/kg) and another three groups of TBC-1269 given at 40 mg/kg at different times of administration: 15 min prereperfusion but after ischemia (no pretreatment), at the time of reperfusion, and at 15 min after reperfusion. The parameters measured at 3 h of reperfusion included liver function tests (alanine aminotransferase and aspartate aminotransferase), histopathology analysis and measurements using enzyme-linked immunosorbent assay in serum of TNF-α and IL-10. Statistical analysis included analysis of variance with P values of <0.05 for significance. Results were expressed as mean ± SD. The liver function tests showed statistically significant differences between the ischemic control group and both the sham group and the group treated with 40 mg/kg at the time of reperfusion ([email protected]). These results correlated well with the histopathological analysis in that we found no difference in vacuolization, congestion, and necrosis between the [email protected] group and the sham group. The TNF-α and the IL-10 also reflected the protection observed in histopathology, with a decrease in TNF- α from the high levels observed in the IC (32 ± 2.32 pg/mL) to a lower level of 8.5 ± 4.04 mg observed in the [email protected] group, and an increment in the levels of the protective IL-10 from 2.8 ± 2.9 pg/mL in the IC group versus 37.9 ± 11.6 pg/mL in the [email protected] treated group (P < 0.05). Lower doses and different times of administration of TBC-1269 did not show a protective effect. The IC group showed no difference in damage by histopathology or liver enzymes compared to the rest of the groups, except the [email protected] group. In this work, we demonstrated that the small molecule multiple selectin inhibitor (TBC-1269) offered significant protection for the ischemic liver when given at 40 mg/kg at the time of perfusion. Lower doses and different times of administration did not show the optimal drug effect. The protection observed in the liver function tests (alanine aminotransferase and aspartate aminotransferase) and histopathology in this group was also reflected in the significant decrease in serum TNF-α and equally significant increase in serum protective IL-10." @default.
- W2113699432 created "2016-06-24" @default.
- W2113699432 creator A5051860632 @default.
- W2113699432 creator A5058292643 @default.
- W2113699432 date "2007-04-01" @default.
- W2113699432 modified "2023-10-16" @default.
- W2113699432 title "Anti-Ischemic Effect of Selectin Blocker Through Modulation of Tumor Necrosis Factor-α and Interleukin-10" @default.
- W2113699432 cites W162447880 @default.
- W2113699432 cites W1666118439 @default.
- W2113699432 cites W1965892013 @default.
- W2113699432 cites W1966172072 @default.
- W2113699432 cites W1970665368 @default.
- W2113699432 cites W1982584622 @default.
- W2113699432 cites W1983020719 @default.
- W2113699432 cites W1990593837 @default.
- W2113699432 cites W1998725389 @default.
- W2113699432 cites W2007663747 @default.
- W2113699432 cites W2007829414 @default.
- W2113699432 cites W2016892309 @default.
- W2113699432 cites W2034338667 @default.
- W2113699432 cites W2036500213 @default.
- W2113699432 cites W2040052549 @default.
- W2113699432 cites W2041469322 @default.
- W2113699432 cites W2041689111 @default.
- W2113699432 cites W2044884889 @default.
- W2113699432 cites W2046348302 @default.
- W2113699432 cites W2046407094 @default.
- W2113699432 cites W2046586570 @default.
- W2113699432 cites W2047502767 @default.
- W2113699432 cites W2062262820 @default.
- W2113699432 cites W2062794300 @default.
- W2113699432 cites W2075690073 @default.
- W2113699432 cites W2078198072 @default.
- W2113699432 cites W2081946593 @default.
- W2113699432 cites W2083655526 @default.
- W2113699432 cites W2087054106 @default.
- W2113699432 cites W2098277628 @default.
- W2113699432 cites W2101771134 @default.
- W2113699432 cites W2127191881 @default.
- W2113699432 cites W2130436432 @default.
- W2113699432 cites W2141645623 @default.
- W2113699432 cites W2142071589 @default.
- W2113699432 cites W2142955470 @default.
- W2113699432 cites W2160800132 @default.
- W2113699432 cites W2191654227 @default.
- W2113699432 cites W2266998221 @default.
- W2113699432 cites W2342065462 @default.
- W2113699432 cites W4246876127 @default.
- W2113699432 doi "https://doi.org/10.1016/j.jss.2006.04.012" @default.
- W2113699432 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17254609" @default.
- W2113699432 hasPublicationYear "2007" @default.
- W2113699432 type Work @default.
- W2113699432 sameAs 2113699432 @default.
- W2113699432 citedByCount "18" @default.
- W2113699432 countsByYear W21136994322012 @default.
- W2113699432 countsByYear W21136994322013 @default.
- W2113699432 countsByYear W21136994322016 @default.
- W2113699432 countsByYear W21136994322018 @default.
- W2113699432 countsByYear W21136994322019 @default.
- W2113699432 countsByYear W21136994322021 @default.
- W2113699432 crossrefType "journal-article" @default.
- W2113699432 hasAuthorship W2113699432A5051860632 @default.
- W2113699432 hasAuthorship W2113699432A5058292643 @default.
- W2113699432 hasConcept C126322002 @default.
- W2113699432 hasConcept C134018914 @default.
- W2113699432 hasConcept C142724271 @default.
- W2113699432 hasConcept C17991360 @default.
- W2113699432 hasConcept C2780114680 @default.
- W2113699432 hasConcept C2992208098 @default.
- W2113699432 hasConcept C503630168 @default.
- W2113699432 hasConcept C541997718 @default.
- W2113699432 hasConcept C544855455 @default.
- W2113699432 hasConcept C71924100 @default.
- W2113699432 hasConcept C90924648 @default.
- W2113699432 hasConcept C99476002 @default.
- W2113699432 hasConceptScore W2113699432C126322002 @default.
- W2113699432 hasConceptScore W2113699432C134018914 @default.
- W2113699432 hasConceptScore W2113699432C142724271 @default.
- W2113699432 hasConceptScore W2113699432C17991360 @default.
- W2113699432 hasConceptScore W2113699432C2780114680 @default.
- W2113699432 hasConceptScore W2113699432C2992208098 @default.
- W2113699432 hasConceptScore W2113699432C503630168 @default.
- W2113699432 hasConceptScore W2113699432C541997718 @default.
- W2113699432 hasConceptScore W2113699432C544855455 @default.
- W2113699432 hasConceptScore W2113699432C71924100 @default.
- W2113699432 hasConceptScore W2113699432C90924648 @default.
- W2113699432 hasConceptScore W2113699432C99476002 @default.
- W2113699432 hasIssue "2" @default.
- W2113699432 hasLocation W21136994321 @default.
- W2113699432 hasLocation W21136994322 @default.
- W2113699432 hasOpenAccess W2113699432 @default.
- W2113699432 hasPrimaryLocation W21136994321 @default.
- W2113699432 hasRelatedWork W2047452716 @default.
- W2113699432 hasRelatedWork W2115661411 @default.
- W2113699432 hasRelatedWork W2399391471 @default.
- W2113699432 hasRelatedWork W2400254106 @default.
- W2113699432 hasRelatedWork W2970729894 @default.
- W2113699432 hasRelatedWork W3039419443 @default.